Global Biosimilar Monoclonal Antibodies Market Trends And Strategies Of Major Players In The Biosimilar Monoclonal Antibodies Market 2021-2030
8 Dec, 2021
Global Biosimilar Monoclonal Antibodies Market Size And Drivers:
The global biosimilar monoclonal antibodies market is expected to grow from $3.52 billion in 2020 to $4.33 billion in 2021 at a compound annual growth rate (CAGR) of 23%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar MAbs market is expected to reach $10.92 billion in 2025 at a CAGR of 26%. The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market.
Request For A Sample For The Global Biosimilar Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
Trends In The Global Biosimilar Monoclonal Antibodies Market
The focus areas for many companies in the biosimilar monoclonal antibodies market has shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets. As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another instance, in May 2020, AbbVie, a US-based biopharmaceutical company, announced its decision to acquire Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies
Global Biosimilar Monoclonal Antibodies Market Segments:
The global biosimilar MAbs market is further segmented –
By Type: Synthetic Chemicals, Biopharmaceuticals, Others
By Application: Chronic & Autoimmune Diseases, Oncology, Others
By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
By Geography: The global biosimilar monoclonal antibodies market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Report For The Global Biosimilar Monoclonal Antibodies Market At:
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-changeBiosimilar Monoclonal Antibodies Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market overviews, analyzes and forecasts market size and growth for the global biosimilar monoclonal antibodies market, biosimilar monoclonal antibodies market share, biosimilar monoclonal antibodies market players, biosimilar monoclonal antibodies market segments and geographies, biosimilar monoclonal antibodies market’s leading competitors’ revenues, profiles and market shares. The biosimilar monoclonal antibodies market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.